Pazufloxacin - Lees Pharmaceutical Holdings

Drug Profile

Pazufloxacin - Lees Pharmaceutical Holdings

Alternative Names: Pazufloxacin mesilate - Lees Pharmaceutical Holdings

Latest Information Update: 10 Nov 2015

Price : $50

At a glance

  • Originator Lees Pharmaceutical Holdings
  • Class Antibacterials; Fluoroquinolones; Oxazines; Small molecules
  • Mechanism of Action Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Otitis media

Most Recent Events

  • 01 Jul 2015 Phase-I clinical trials in Otitis media in China (Otic) (NCT02592096)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top